

PROLIGHT SELECTED AS SEMI-FINALIST FOR ADLM 2026 DISRUPTIVE TECHNOLOGY AWARD COMPETITION

Prolight Diagnostics, pioneer of point-of-care technology, today announces that they have been selected as a semi-finalist for the prestigious Disruptive Technology Award Competition (DTAC) organized by the Association for Diagnostics and Laboratory Medicine (ADLM). As a DTAC semi-finalist, Prolight are guaranteed exhibition space in the Disruptive Technology area at the ADLM annual meeting in Anaheim, California, July 26th-30th 2026.

The six semi-finalists will present their technologies to the DTAC committee in early May to select three finalists who will present at a plenary session of the ADLM annual meeting in Anaheim, California on the 27th July. The winner will be selected at this session.

"We are delighted to be selected as semi-finalist for this prestigious award, which demonstrates the rapid progress we are making with our single-molecule-counting point-of-care technology", said Ulf Bladin, CEO of Prolight. "Being selected as a semi-finalist is a clear testament to the disruptive nature of our technology, with this independent validation from a panel of industry experts serving as a strong endorsement of its capabilities."

The ADLM 2026 Annual Scientific Meeting & Clinical Lab Expo is the premier global event for diagnostics and laboratory medicine with over 20,000 expected attendees and more than 800 exhibitors. The event features more than 250 educational sessions, covering a wide range of disciplines across diagnostics.

The Disruptive Technology Award was launched in 2018 to identify groundbreaking technologies that could transform the diagnostics industry. Their Mission Statement is: "ADLM's Disruptive Technology Award Competition (DTAC) aims to evaluate and elevate companies developing new diagnostic tools and technologies that have the potential to improve patient care. DTAC grants the diagnostic and laboratory medicine community an early look at innovative and impactful products that address current gaps in the field and/or improve upon existing solutions."

The official announcement of the DTAC semifinalists is available here: <https://meeting.myadlm.org/conference-program/disruptive-technology-award/contestants>

Further information on ADLM can be found here: <https://meeting.myadlm.org/about>

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight selected as semi-finalist for ADLM 2026 Disruptive Technology Award Competition